TG THERAPEUTICS, INC. — Director's Dealing 2023

Aug 14, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TG THERAPEUTICS, INC. (TGTX)
CIK: 0001001316
Period of Report: 2023-08-11

Reporting Person: WEISS MICHAEL S (Director, CEO and President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-08-11	COMMON STOCK	P	100000	$10.13	Acquired	12073021	Direct

Footnotes

F1: Reflects the weighted average purchase price. The range of prices for the shares purchased was $10.11 to $10.17. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.

F2: Includes shares of restricted Common Stock, which vest over various time periods.